John Newman
Stock Analyst at Canaccord Genuity
(1.24)
# 3,743
Out of 5,245 analysts
91
Total ratings
35%
Success rate
-13.07%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,057 → $875 | $638.88 | +36.96% | 21 | May 19, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Buy | $23 | $8.55 | +169.01% | 1 | May 11, 2026 | |
| ATRA Atara Biotherapeutics | Upgrades: Buy | $6 → $13 | $9.80 | +32.65% | 8 | May 8, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $171 → $158 | $92.14 | +71.48% | 10 | May 6, 2026 | |
| CMPX Compass Therapeutics | Maintains: Buy | $13 → $7 | $2.07 | +238.16% | 2 | Apr 28, 2026 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $9 | $1.30 | +592.31% | 1 | Apr 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Buy | $50 | $32.47 | +53.99% | 1 | Apr 6, 2026 | |
| TNGX Tango Therapeutics | Initiates: Buy | $30 | $20.24 | +48.22% | 1 | Apr 2, 2026 | |
| MCRB Seres Therapeutics | Maintains: Buy | $22 | $7.92 | +177.78% | 11 | Mar 13, 2026 | |
| CADL Candel Therapeutics | Maintains: Buy | $25 | $7.99 | +212.89% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 | $2.00 | +600.00% | 4 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $18 | $8.30 | +116.87% | 7 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $126 | $102.12 | +23.38% | 1 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $11.04 | +90.22% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.40 | +471.43% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.76 | +536.09% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.8095 | +517.67% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $28.14 | +56.36% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $11.99 | +216.93% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $1.55 | +1,641.94% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.22 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
May 19, 2026
Maintains: Buy
Price Target: $1,057 → $875
Current: $638.88
Upside: +36.96%
BridgeBio Oncology Therapeutics
May 11, 2026
Initiates: Buy
Price Target: $23
Current: $8.55
Upside: +169.01%
Atara Biotherapeutics
May 8, 2026
Upgrades: Buy
Price Target: $6 → $13
Current: $9.80
Upside: +32.65%
BioNTech SE
May 6, 2026
Maintains: Buy
Price Target: $171 → $158
Current: $92.14
Upside: +71.48%
Compass Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $13 → $7
Current: $2.07
Upside: +238.16%
Lineage Cell Therapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $9
Current: $1.30
Upside: +592.31%
Tyra Biosciences
Apr 6, 2026
Initiates: Buy
Price Target: $50
Current: $32.47
Upside: +53.99%
Tango Therapeutics
Apr 2, 2026
Initiates: Buy
Price Target: $30
Current: $20.24
Upside: +48.22%
Seres Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $22
Current: $7.92
Upside: +177.78%
Candel Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $25
Current: $7.99
Upside: +212.89%
Mar 13, 2026
Maintains: Buy
Price Target: $14
Current: $2.00
Upside: +600.00%
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $8.30
Upside: +116.87%
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $102.12
Upside: +23.38%
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $11.04
Upside: +90.22%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.76
Upside: +536.09%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.8095
Upside: +517.67%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $28.14
Upside: +56.36%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $11.99
Upside: +216.93%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $1.55
Upside: +1,641.94%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.22
Upside: -